Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
Details : XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).
Brand Name : XEN496
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2021
Details : Xenon has received a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), which recommends the granting of an orphan medicinal product designation for XEN496 for the treatment of KCNQ2-DEE.
Brand Name : XEN496
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 08, 2020
LOOKING FOR A SUPPLIER?
Reset All
